PDSB PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’ Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501. | ||
 PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny The latest update cuts the fair value price target for PDS Biotechnology from US$5.75 to US$4.75, signaling a more conservative valuation anchor for the stock. Analysts link this change to a mix of optimism around the refocused emphasis on PDS0301 and caution about funding needs, execution risks, and the structure of the Nant led financing. As you read on, you will see how these moving pieces shape the evolving story around PDS Biotechnology and what to watch next. Stay updated as the Fair... | ||
 ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last? ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. | ||
 This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close. | ||
 IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform. | ||